Trivehexin is one of the 24 subtypes of integrin. It is a strong promotor of TGF-β activation, favoring tumor invasion and metastasis. It is expressed by epithelial cells and is highly overexpressed by carcinomas and fibrotic tissues. Due to this unique feature, it is used in the diagnosis of Pancreatic Ductal Adenocarcinoma (PDAC), head and neck cancers (HNSCC), idiopathic pulmonary fibrosis (IPF) and non-small cell lung cancers (NSCLC).
